Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon2.,
Disease:Adenocarcinoma
Product details:
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-APPL1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
APPL also known as Adaptor Protein Phosphotyrosine Interaction PH Domain and Leucine Zipper Containing 1 (APPL1) is an adaptor protein that plays an important role in cellular signal transduction. APPL1 has a molecular mass of approximately 80 kDa. It is widely expressed in various tissues including the brain liver and skeletal muscle. APPL1 binds to many other proteins via its pleckstrin homology (PH) domain and a leucine zipper domain playing a role in diverse signaling pathways.
Biological function summary
APPL1 influences cellular processes such as endocytosis and cell proliferation. APPL1 interacts with rab5 forming a component of endosomal signaling complexes. This interaction drives the early endocytic process influencing cell surface receptor trafficking. APPL1 also modulates insulin signaling by binding to proteins like the insulin receptor substrate affecting glucose metabolism and cellular energy balance.
Pathways
APPL1 acts in the AKT signaling pathway and the adiponectin signaling pathway. In the AKT pathway APPL1 operates with proteins like AKT itself and GSK3β contributing to cell survival and growth. It assists the adiponectin pathway by facilitating interactions between adiponectin receptors and downstream effectors impacting lipid metabolism and insulin sensitivity. APPL1's involvement in these pathways highlights its multifaceted regulatory roles in cellular metabolism and response to stimuli.
APPL1 exhibits associations with type 2 diabetes and certain cancers. APPL1 influences insulin sensitivity a critical factor in type 2 diabetes pathogenesis. It interacts with proteins like adiponectin and the insulin receptor substrate playing a part in glucose homeostasis. In cancer APPL1's role in AKT signaling can influence tumor growth and survival linking it to dysregulation in cancers such as breast cancer. The ability of APPL1 to modulate key signaling pathways highlights its importance in understanding these diseases.
